DarioHealth (DRIO) Cash & Equivalents (2012 - 2026)

DarioHealth (DRIO) has reported Cash & Equivalents for 15 consecutive years, with $6.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 69.78% year-over-year to $6.6 million; the trailing twelve-month figure through Jun 2026 stood at $6.6 million (down 69.78% YoY), and the FY2025 full-year result was $21.8 million, down 21.47% from the prior year.
• Cash & Equivalents eased to $6.6 million in Q2 2026 per DRIO's latest filing, from $15.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $67.9 million in Q2 2022 and bottomed at $6.6 million in Q2 2026.
• Historically, Cash & Equivalents has averaged $34.9 million across 5 years, with a median of $33.1 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents surged 105.23% in 2025, then slumped 69.78% in 2026.
• Over 5 years, Cash & Equivalents stood at $49.4 million in 2022, then dropped by 25.45% to $36.8 million in 2023, then declined by 24.55% to $27.8 million in 2024, then decreased by 21.47% to $21.8 million in 2025, then sank by 69.57% to $6.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $6.6 million, $15.0 million, and $21.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.